- Home
- EDSA vs SNTI Comparison
EDSA vs SNTI Comparison
Compare EDSA & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDSA
- SNTI
- Stock Information
- Founded
- EDSA 2015
- SNTI 2016
- Country
- EDSA Canada
- SNTI United States
- Employees
- EDSA N/A
- SNTI N/A
- Industry
- EDSA Biotechnology: Pharmaceutical Preparations
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- EDSA Health Care
- SNTI Health Care
- Exchange
- EDSA Nasdaq
- SNTI Nasdaq
- Market Cap
- EDSA 13.8M
- SNTI 14.1M
- IPO Year
- EDSA N/A
- SNTI N/A
- Fundamental
- Price
- EDSA $4.30
- SNTI $2.28
- Analyst Decision
- EDSA Strong Buy
- SNTI
- Analyst Count
- EDSA 2
- SNTI 0
- Target Price
- EDSA $39.00
- SNTI N/A
- AVG Volume (30 Days)
- EDSA 10.6K
- SNTI 20.3K
- Earning Date
- EDSA 08-09-2024
- SNTI 11-11-2024
- Dividend Yield
- EDSA N/A
- SNTI N/A
- EPS Growth
- EDSA N/A
- SNTI N/A
- EPS
- EDSA N/A
- SNTI N/A
- Revenue
- EDSA N/A
- SNTI $338,000.00
- Revenue This Year
- EDSA N/A
- SNTI $254.47
- Revenue Next Year
- EDSA N/A
- SNTI $169.66
- P/E Ratio
- EDSA N/A
- SNTI N/A
- Revenue Growth
- EDSA N/A
- SNTI N/A
- 52 Week Low
- EDSA $2.46
- SNTI $1.52
- 52 Week High
- EDSA $8.33
- SNTI $8.48
- Technical
- Relative Strength Index (RSI)
- EDSA 48.15
- SNTI 42.60
- Support Level
- EDSA $4.13
- SNTI $2.05
- Resistance Level
- EDSA $4.44
- SNTI $2.48
- Average True Range (ATR)
- EDSA 0.22
- SNTI 0.23
- MACD
- EDSA -0.00
- SNTI -0.04
- Stochastic Oscillator
- EDSA 25.29
- SNTI 24.19
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company operates in a single segment: research and development, manufacturing, and commercialization of innovative pharmaceutical products. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.